Mainz Biomed reviews accomplishments for first half of 2025

Mainz Biomed (MYNZ) reviewed its major accomplishments of the first six months ending June 30, 2025, and provided a corporate update. The Company expects to release its half year financial results in September 2025. Key Highlights During First Half 2025: Mainz Biomed launched eAArly DETECT 2; The Company entered into a strategic partnership with labor team w ag, a renowned diagnostic laboratory based in Goldach, Switzerland; Mainz Biomed entered into a technology partnership with UK-based EDX Medical Group; Mainz Biomed entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA biomarkers for the non-invasive detection of pancreatic cancer with a blood test; The Company announced the commencement of the next phase in its PancAlert project; Mainz Biomed announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz; The Company received formal notice from The Nasdaq Stock Market confirming that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1); Mainz Biomed priced a follow-on offering of 2,000,000 units.